Viking Therapeutics, Inc. (LON:0VQA)
London flag London · Delayed Price · Currency is GBP · Price in USD
31.82
+4.54 (16.64%)
Feb 12, 2026, 5:09 PM GMT

Viking Therapeutics Company Description

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.

The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics, Inc.
CountryUnited States
Founded2012
IndustryMedical - Pharmaceuticals
SectorHealthcare
Employees51
CEOBrian Lian

Contact Details

Address:
9920 Pacific Heights Boulevard
San Diego, California 92121
United States
Phone858 704 4660
Websitevikingtherapeutics.com

Stock Details

Ticker Symbol0VQA
ExchangeLondon Stock Exchange
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS92686J1060
SIC Code2836

Key Executives

NamePosition
Dr. Brian Lian Ph.D.President, Chief Executive Officer and Director
Gregory S. Zante CPAChief Financial Officer
Marianne ManciniChief Operating Officer
Michael MorneauVice President of Finance and Administration
Dr. Geoffrey E. Barker Ph.D.Chief Development Officer
Neil Aubuchon B.A., M.B.A.Chief Commercial Officer
Dr. Nils U. Olsson Ph.D.Senior Vice President of Technical Operations
Kenneth HermanSenior Vice President of Commercial